UroGen Pharma (URGN) Shares Outstanding (2016 - 2026)
UroGen Pharma's (URGN) quarterly Shares Outstanding (Entity) came in at $48.7 million in Q1 2026, up 5.65% YoY from $46.1 million in Q1 2025, and up 0.74% on a QoQ basis from $48.4 million in Q4 2025.
UroGen Pharma (URGN) Shares Outstanding (2016 - 2026) Analysis & Trends
UroGen Pharma (URGN) has 11 years of Shares Outstanding (Entity) data on file, last reported at $48.7 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 5.65% year-over-year to $48.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.7 million (up 5.65% YoY) and the FY2025 annual result came in at $48.4 million, up 14.49% from the prior year.
- Shares Outstanding (Entity) grew to $48.7 million in Q1 2026, from $48.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $48.7 million in Q1 2026 to a low of $22.7 million in Q1 2022.
- A 5-year average of $35.3 million and a median of $36.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 1.67% — and 2024, when it soared 75.2%.
- Tracing URGN's Shares Outstanding (Entity) over 5 years: stood at $23.1 million in 2022, then surged by 40.47% to $32.5 million in 2023, then rose by 29.98% to $42.2 million in 2024, then advanced by 14.49% to $48.4 million in 2025, then gained by 0.74% to $48.7 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $48.7 million (Q1 2026), $48.4 million (Q4 2025), and $46.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | UroGen Pharma | 2.36 Bn | 2.25 Bn | 65.88 Mn | 50.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.38 Mn |
| Mar 31, 2026 | 50.18 Mn |
| Dec 31, 2025 | 48.12 Mn |
| Sep 30, 2025 | 48.06 Mn |
| Jun 30, 2025 | 47.74 Mn |
| Mar 31, 2025 | 47.42 Mn |
| Dec 31, 2024 | 42.88 Mn |
| Sep 30, 2024 | 43.10 Mn |
| Jun 30, 2024 | 36.82 Mn |
| Mar 31, 2024 | 33.38 Mn |
| Dec 31, 2023 | 28.83 Mn |
| Sep 30, 2023 | 32.30 Mn |
| Jun 30, 2023 | 23.46 Mn |
| Mar 31, 2023 | 23.28 Mn |
| Dec 31, 2022 | 22.81 Mn |
| Sep 30, 2022 | 22.80 Mn |
| Jun 30, 2022 | 22.70 Mn |
| Mar 31, 2022 | 22.63 Mn |
| Dec 31, 2021 | 22.35 Mn |
| Sep 30, 2021 | 22.38 Mn |